Tumor necrosis factor-α impairs endothelium-dependent relaxation of rat renal arteries, independent of tyrosine kinase

Shock

Volumn 17, Issue 5, 2002, Pages 394-398

  Piepot, Harro A ^a   Groeneveld, A B Johan ^a,b   Van Lambalgen, Antonie A ^a   Sipkema, Pieter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acetylcholine; Constriction; Endothelium; Relaxation; Vascular smooth muscle

Indexed keywords

ACETYLCHOLINE; ENZYME INHIBITOR; GENISTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NORADRENALIN; NOS2 PROTEIN, RAT; POTASSIUM CHLORIDE; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VASOCONSTRICTOR AGENT;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; MALE; METABOLISM; MUSCLE RELAXATION; PHYSIOLOGY; RAT; RENAL ARTERY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GENISTEIN; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NOREPINEPHRINE; POTASSIUM CHLORIDE; PROTEIN-TYROSINE KINASES; RATS; RATS, WISTAR; RENAL ARTERY; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0036581841     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200205000-00009     Document Type: Article

References (40)

1. Szabó C, Mitchell JA, Thiemermann C, Vane JR: Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 108:786-792, 1993.
2. Piepot HA, Boer C, Groeneveld ABJ, van Lambalgen AA, Sipkema P: Lipopolysaccharide impairs endothelial nitric oxide synthesis in rat renal arteries. Kidney Int 57:2502-2510, 2000.
3. Xie J, Wang Y, Lippton H, Cai B, Nelson S, Kolls J, Summer WR, Greenberg SS: Tumor necrosis factor inhibits stimulated but not basal release of nitric oxide. Am Rev Resp Dis 148:627-636, 1993.
4. Wang P, Ba ZF, Chaudry IH: Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 266:H2535-H2541, 1994.
5. Lu JL, Schmiege LM, Kuo L, Liao JC: Down-regulation of endothelial constitutive nitric oxide synthase expression by lipopolysaccharide. Biochem Biophys Res Commun 225:1-5, 1996.
6. Zhang J, Patel JM, Li YD, Block ER: Proinflammatory cytokines down-regulate gene expression and activity of constitutive nitric oxide synthase in porcine pulmonary artery endothelial cells. Res Commun Mol Pathol Pharmacol 96:71-87, 1997.
7. Yamashhita T, Kawashima S, Ohashi Y, Ozaki M, Ueyama T, Ishida T, Inoue N, Hirata K-I, Akita H, Yakoyama M: Resistance to endotoxin shock in transgenic mice overexpressing endothelial nitric oxide synthase. Circulation 101: 931-937, 2000.
8. Griffith OW, Stuehr DJ: Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 57:707-736, 1995.
9. Ju H, Zou R, Venema VJ, Venema RC: Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 272: 18522-18525, 1997.
10. Feron O, Saldana F, Michel JB, Michel T: The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 273:3125-3128, 1998.
11. Prabhakar P, Thatte HS, Goetz RM, Cho MR, Golan DE, Michel T: Receptor-regulated translocation of endothelial nitric oxide synthase. J Biol Chem 273: 27383-27388, 1998.
12. García-Cardeña G, Fan R, Stern DF. Liu J, Sessa WC: Endothelial nitric oxide is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 271:27237-27240, 1996.
13. Venema VJ, Marrero MB, Venema RC: Bradykinin-stimulated protein tyrosine phosphorylation promotes endothelial nitric oxide synthase translocation to the cytoskeleton. Biochem Biophys Res Commun 226:703-710, 1996.
14. 2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res 82:686-695, 1998.
15. Guy GR, Chua SP, Wong NS, Ng SB, Tan YH: Interleukin-1 and tumor necrosis factor activate common multiple protein kinases in human fibroblasts. J Biol Chem 266:14343-14352, 1991.
16. Muñoz E, Zubiaga A, Huang C, Huber BT: Interleukin-1 induces protein tyrosine phosphorylation in T cells. Eur J Immunol 22:1391-1396, 1992.
17. Dong Z, Qi X, Fidler IJ: Protein tyrosine kinase inhibitors decrease the induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages. J Immunol 151:2717-2724, 1993.
18. Geng Y, Zhang B, Lotz M: Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. J Immunol 151:6692-6700, 1993.
19. Marczin N, Papapetropoulos A, Catravas JD: Tyrosine kinase inhibitors suppress endotoxin- and IL-1α-induced NO synthesis in aortic smooth muscle cells. Am J Physiol 265:H1014-H1018, 1993.
20. Schumann RR, Pfeil D, Lamping N, Kirschning C, Scherzinger G, Schlag P, Karawajew L, Hermann F: Lipopolysaccharide induces the rapid tyrosine phosphorylation of the mitogen-activated protein kinases erk-1 and p38 in cultured human vascular endothelial cells requiring the presence of soluble CD 14. Blood 87:2805-2814, 1996.
21. Joly GA, Ayres M, Kilbourn KG: Potent inhibition of inducible nitric oxide synthase by geldanamycin, a tyrosine kinase inhibitor, in endothelial, smooth muscle cells, and in rat aorta. FEBS Lett 403:40-44, 1997.
22. Zheng X-L, Gui Y, Sharkey KA, Hollenberg MD: Differential induction of nitric oxide synthase in rat gastric and vascular smooth muscle tissue: distinct tissue distribution and distinctive signaling pathways. J Pharmacol Exp Ther 289:632-640, 1999.
23. Akiyama T, Ishada J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592-5595, 1987.
24. Novogrodsky A, Vanichkin A, Patya M, Gazit A, Osherov N, Levitzki A: Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science 264:1319-1322, 1994.
25. Moritoki H, Hisayama T, Takeuchi S, Kondoh W, Takeji Y: Possible involvement of tyrosine kinase in the LPS-promoted initiation of L-arginine-induced relaxation of rat aorta mediated by induction of NO synthase. Life Sci 57:PL125-PL130, 1995.
26. Vanickin A, Patya M, Gazit A, Levitzki A, Novogrodsky A: Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity. J Infect Dis 173:927-933, 1996.
27. Duarte J, Ocete MA, Pérez-Vizcaino F, Zarzuelo A, Tamargo J: Effects of tyrosine kinase and tyrosine phosphatase inhibitors on aortic contraction and induction of nitric oxide synthase. Eur J Pharmacol 338:25-33, 1997.
28. Ruetten ZH, Thiemermann C: Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase. Br J Pharmacol 122:59-70, 1997.
29. Sevransky JE, Shaked G, Novogrodsky A, Levitzki A, Gazit A, Hoffman A, Elin RJ, Quezado ZMN, Freeman BD, Eichacker PQ, Danner RL, Banks SM, Bacher J, Thomas III ML, Natanson C: Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J Clin Invest 99:1966-1973, 1997.
30. Cochran JB, Genovese F, Romeo C, Guyton K, Teti G, Cook JA: The effect of a tyrosine kinase inhibitor on endotoxin mortality and splenocyte mediator production in the neonatal rat. Shock 11:35-38, 1999.
31. Ogura S, Umegaki O, Genovese F, Fernando LP, Cochran JB, Romeo CM, Cook JA: Protective effect of tyrphostin AG-556 on shock induced by endotoxin or gram-positive bacteria. Shock 12:105-110, 1999.
32. Bhagat K, Moss R, Collier J, Vallance P: Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 32:822-829, 1996.
33. 2+ mobilization and nitric oxide biosynthesis in cultured endothelial cells. Circ Res 75:659-668, 1994.
34. Jayaraman T, Ondrias K, Ondriasova E, Marks AR: Regulation of the inositol 1,4,5-triphosphate receptor by tyrosine phosphorylation. Science 272:1492-1494, 1996.
35. Kitazono T, Ibayashi S, Nagao T, Fujii K, Kagiyama T, Fujishima M: Role of tyrosine kinase in dilator responses of rat basilar artery in vivo. Hypertension 31:861-865, 1998.
36. Jinsi A, Paradise J, Deth RC: A tyrosine kinase regulated α-adrenoceptor-stimulated contraction and phospholipase D activation in the rat aorta. Eur J Pharmacol 302:183-190, 1996.
37. Di Salvo J, Steusloff A, Semenchuk L, Satoh S, Kolquist K, Pfitzer G: Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun 190:968-974, 1993.
38. Filipeanu CM, Brailoiu E, Huhurez G, Slatineanu S, Baltatu O, Branisteanu DD: Multiple effects of tyrosine kinase inhibitors on vascular smooth muscle contraction. Eur J Pharmacol 281:29-35, 1995.
39. Spurrell BE, Murphy TV, Hill MA: Tyrosine phosphorylation modulates arteriolar tone but is not fundamental to myogenic response. Am J Physiol 278:H373-H382, 2000.
40. Chatterjee M, Tejada M: Phorbol ester-induced contraction in chemically skinned vascular smooth muscle. Am J Physiol 251:C356-C361, 1986.